University of Southampton
Unveiling microbial metabolism: Metabolomic applications in deciphering gut-brain communications for early neurodegeneration
Abstract
dc:description.abstractNeurodegenerative diseases such as Alzheimer’s disease (AD) are major causes of debilitation and mortality in ageing adults. With limited treatments, preventative management of early neurodegeneration before it progresses to AD is a priority. Early probiotic and prebiotic trials, along with preclinical studies implicate microbial modifications in improving various outcomes of early neurodegeneration, including cognition. Despite these improvements, the microbial mechanisms that facilitate them remain largely unknown. Preclinical studies have established the microbiota-gut-brain axis, a communication channel between the microbiota and host, as a potential mediator of the neurodegenerative outcomes; with emerging interest in gut-produced metabolites as biofunctional directors of this axis. To explore the mechanisms facilitated through microbial modifications and metabolites in respect to early neurodegeneration, a series of metabolomic profiling studies were developed to shed light on the biochemical interactions between gut metabolites and host health with a focus on circulatory-based interactions of the microbiota-gut-brain axis. First, a series of preclinical experiments were developed to measure the effects of microbial metabolites before exploring the significance of microbial-produced metabolites in an ageing cohort with developing cognitive impairment. A metabolomic screening pipeline was developed to assess the neuroactive potential of metabolites produced from probiotic candidates. An optimal strain (L. plantarum – Lpldl®) was selected for further study based on its production of gut-relevant metabolites (glutamine, choline, lactate). Following, in vivo models were devised to explore how microbial supplements (WellBiome®, Lpldl® and L. brevis) influence the brain metabolome using wild-type and tauopathy Drosophila melanogaster – as a model of early neurodegeneration. Supplements were more influential on the wild-type brain profiles with consistent changes to choline metabolites; though none of the supplements improved outcomes of cognition, longevity or brain levels of phosphorylated tau. Finally, serum from a human cohort developing cognitive impairment was profiled. Multivariate results revealed serum metabolomes had sex-specific predictive responses. Male serum profiles were predictive of cognition (Q2 0.17; p < 0.053) while female profiles were predictive of inflammatory markers including p-tau217 (Q2 0.34; p < 0.02), an emerging biomarker of AD. Collectively profiling across the circulatory compartments of the microbiota-gut-brain axis outlined consistent microbiota-driven mechanisms that could contribute to the restorative effects of microbial supplements on early neurodegenerative outcomes. Most prominently, energy-related metabolites like lactate, citric acid intermediates and short-chain fatty acids were consistently identified that indicated the microbiota supports host energy homeostasis as an indirectly neuroprotective mechanism. Furthermore, while microbial modification only subtly changed neurotransmitters in the brain metabolome, glycine – a neurotransmitter important in cognitive processes – was consistently identified throughout profiling. Serum glycine was significantly lower in adults with mildly impaired cognition (p < 0.03), produced by the probiotics L. plantarum (Lpldl®) and L. plantarum and the final intermediate implied in the shift in choline metabolism which suggests the microbiota may modify choline metabolism to regulate neurotransmitter levels. In summary, profiling outlined energy homeostasis, choline metabolism and neurotransmitter modulation as key mechanisms facilitated through microbial modulation, as established from their consistent metabolite interactions. These metabolite-directed responses could be relevant for further validation studies to clarify their biological significance and assess the use of probiotics and prebiotics in the prevention of early neurodegeneration.
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D.
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Southampton
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Harvey, Michael Luke
- Advisors dc:contributor.advisor
-
- Swann, Jonathan
- Tuohy, Kieran
- Childs, Caroline
- Kolida, Sofia
- ORCID person:identifier.orcid
Rights
- Language dc:language
- English, eng
Identifiers
dc:identifier.*- DOI dc:identifier.doi
- https://doi.org/10.5258/SOTON/PG/T174